Lhasa Limited shared knowledge shared progress

Archive

This is a library of Lhasa's blog articles. 

  • 10 tips 
for controlling 
your potentially mutagenic impurities outside the lab.
    Clock: less than 5 minutesless than 5 minutes

    10 tips for controlling your potentially mutagenic impurities outside the lab

    Many readers of this blog will be aware of the threat posed by potentially mutagenic impurities within drug substance synthesis. Such impurities often arise from reagents which are critical to the synthesis therefore this impurity-related threat is unavoidable.

    As such, there is a need to assess the risk posed by mutagenic impurities.

    30 June 2021

  • A day in the life of a Mirabilis Scientist at Lhasa Limited
    Clock: less than 5 minutesless than 5 minutes

    A day in the life of a Scientist at Lhasa Limited

    Discover a day in the life of a Mirabilis Research Scientist at Lhasa Limited! 

    28 May 2021

  • Accessing vital sources of 
long-term carcinogenicity study data 
- Discussing the recent LCDB release features in more detail
    Clock: 5 minutes5 minutes

    Accessing vital sources of long-term carcinogenicity study data with Lhasa’s Carcinogenicity Database

    In this blog piece, we explore in more detail, the features of the recent release and how they will benefit LCDB users.

    12 July 2021

  • Collaboration Innovation Working together data sharing
    Clock: less than 5 minutesless than 5 minutes

    Anticipating and supporting the needs of our members

    As a member-based organisation, anticipating and supporting the needs of our members is critical. 

    31 July 2020

  • image portraying data sharing and two ssystems coming together
    Clock: 5 minutes5 minutes

    Comparing CPDB and Lhasa TD50 values in the Lhasa Carcinogenicity Database

    For many years the Carcinogenic Potency Database (CPDB)1, created by Lois Gold and her team, was an important source of long-term carcinogenicity study data. However, as the database had stopped being updated from 2007, Lhasa moved to safeguard the data by providing ongoing access through a freely available interface; the Lhasa Carcinogenicity Database (LCDB)2. The LCDB was released in 2016 and has since been updated with additional data from the National Toxicology Program (NTP)3, increasing the data set to 7,745 studies covering 1,726 chemical substances. A recent update has also facilitated greater ease of access by enabling substructure and similarity-based structure queries.

    08 December 2020

  • Expert Review Magnifying Glass Results
    Clock: 10 minutes10 minutes

    Human review of in silico predictions of toxicity

    The speed by which models for toxicity prediction can be built and the accuracy with which they can make predictions, have both improved greatly in recent years as a result of advances in technology, mechanistic understanding and access to data.

    21 May 2020

  • Teamwork blog shutterstock
    Clock: less than 5 minutesless than 5 minutes

    It Takes a Team to Build an Adverse Outcome Pathway

    The saying goes, “It takes a village to raise a child”. This sentiment can be translated to the work we do at Lhasa Limited, particularly to the work which we put into building Adverse Outcome Pathways (AOPs). To echo the sentiment in Chris Barber’s previous blog post, The challenge of building QSAR models; it is easy to build an AOP, harder to build a useful AOP, and as for building an AOP you can trust? It takes a team.

    Read about how we are building adverse outcome pathways (AOPs) at Lhasa in this blog post written by Dr. Susanne Stalford, Senior Scientist at Lhasa.

     

    30 September 2020

  • Image for solubility purge best practice blog
    Clock: 5 minutes5 minutes

    Lhasa Limited collaborates with industry and regulators to define solubility purge best practice

    Key to the regulatory acceptance of purge arguments is the conservatism within the purge factor scoring system, which for reactivity purge has been demonstrated across a number of publications and is consistently implemented across the pharmaceutical industry through the development of a collective understanding of and how they should be applied.

    Likewise, when volatility purge scoring is relatively simple to understand and apply, particularly using the scoring thresholds originally proposed by Teasdale et al.

    However, through our interactions with Mirabilis users, regulators, and other members of the purge community, it has become increasingly apparent that the same cannot be said of solubility purge scoring. Lhasa have therefore identified the huge value to the community of developing an accepted best practice, incorporating both the application of solubility purge scoring and, where appropriate, provision of a clear justification of the purge factor assigned.

    29 October 2020

  • Lhasa Limited supports the global challenge of nitrosamine impurity assessment
    Clock: 10 minutes10 minutes

    Lhasa Limited supports the global challenge of nitrosamine impurity assessment

    The recent discovery of N-nitrosamine (nitrosamine) impurities in several marketed pharmaceuticals has led to a requirement for further investigation into nitrosamine mutagenic and carcinogenic activity. Regulatory requirements mean that marketing authorisation holders for human medicines, containing chemically synthesised active substances, must review their medicines for the possible presence of nitrosamines and test all products at risk. Risk-based approaches to prioritise evaluations and subsequent confirmatory testing may be used. These assessments must be completed by October 2020, generating a significant challenge for the pharmaceutical industry.

    13 July 2020

  • A laptop and molecule on a blue background
    Clock: 5 minutes5 minutes

    Predicting forced degradation pathways: Learning how to get the most out of Zeneth

    Are you getting the most out of Zeneth, Lhasa’s expert, knowledge-based in silico software for the prediction of forced degradation pathways of organic active pharmaceutical ingredients (APIs)? 

    19 April 2021

  • Kaptis blog imagery
    Clock: 5 minutes5 minutes

    The Application of Adverse Outcome Pathways (AOPs) for Risk Assessment (A Webinar Summary)

    AOPs have the potential to be very powerful for the contextualisation of alternative assays and consequently for the management of alternative testing strategies. Read about what Lhasa is doing in this area in this blog piece written by Alun Myden, Senior Scientist at Lhasa.

    03 July 2020

  • Computer Software development Models QSAR In Silico 1170x500px
    Clock: 5 minutes5 minutes

    The challenge of building QSAR models

    Building QSAR models is easy. Building useful QSAR models is harder. Building QSAR models you can trust – well that can be really challenging – and this is where a lot of Lhasa’s effort is dedicated – creating models that can be used with confidence to make big decisions – such as those made during a regulatory submission that can protect human safety through exposure of a compound or its impurities! 

    19 May 2020

  • Collaboration Data Sharing Knowledge 1170x500px
    Clock: less than 5 minutesless than 5 minutes

    The Importance of Pre-competitive Collaborations

    Throughout the history of science, progression has relied upon the generation of new knowledge and  then building on that knowledge in order to gain even greater insight. In order to progress, this knowledge needs to be shared as widely as possible.

    26 June 2020

  • Richard Williams 1170x500
    Clock: less than 5 minutesless than 5 minutes

    The Richard Williams Memorial Award

    An award honouring the scientific contributions and memory of Dr. Richard Williams, has been set up to support early career investigators within industry. Supported by the Industrial Genotoxicology Group (IGG), The Richard Williams Memorial Award will sponsor one individual a year to attend and present at the United Kingdom Environmental Mutagen Society (UKEMS) meeting.

    26 July 2020

  • Trusting expert derived knowledge; an overview of alert creation in Derek Nexus
    less than 10 minutes

    Trusting expert derived knowledge; an overview of alert creation in Derek Nexus

    Derek Nexus contains alerts which predict the potential toxicity of a compound, this article explains how Lhasa scientists create alerts which are trustworthy and accurate.

    20 May 2021

  • Handshake
    Clock: 15 minutes15 minutes

    We can apply a lot about how we trust one another when building and using in silico models

    One of the most important ingredients for an effective team is trust, and a critical phase of team building is starting to develop that sense of trust – to be strong has to be earnt and regularly reinforced; it is rarely simply given! The same is true when using in silico models and by mirroring the natural approaches – the intuitive tests that we apply either consciously or subconsciously - we can understand how and when a model can be effectively used.

    15 May 2020

  • Molecules and science abstract image
    Clock: 10 minutes10 minutes

    Zeneth and ICH Q3B

    The ICH Q3B (Impurities in New Drug Products) guideline provides guidance on the qualification of impurities in new drug substances produced by chemical syntheses. This article discusses how Zeneth, Lhasa Limited’s expert decision support software for predicting the forced degradation of organic compounds, can help to satisfy ICH Q3B.

    15 October 2020

© 2021 Lhasa Limited | Registered office: Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK Tel: +44 (0)113 394 6020
VAT number 396 8737 77 | Lhasa Limited is registered as a charity (290866)| Company Registration Number 01765239 (England and Wales).

Apart from the free survey software, we also have access to QuestionPro's free survey templates . We've found many of them useful and powerful to collect insights from various stakeholders of our organization.